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A B S T R A C T
Purpose: Quantitative analysis of epileptiform discharges (EDs) before and after the initiation of an
antiepileptic treatment is a useful tool to objectively documentate the efﬁcacy of an antiepileptic drug
(AED). Aim of this study was to evaluate the effect of levetiracetam (LEV) on EDs, monitored with
ambulatory EEG (A/EEG), in a limited series of patients with generalized epilepsy.
Methods: We performed 24 h A/EEG recording in basal condition and at follow-up after LEV therapy in 21
adult epileptic patients. Eleven received LEV as monotherapy and 10 as add-on. For each patient we
quantiﬁed total epileptic activity considering the following parameters: total number, total duration,
maximal duration and median duration of EDs. Self-reported information on the effect of LEV on clinical
seizures was also collected, to determine the electro-clinical correlation.
Results: A high variability of the response to LEV was observed in the monotherapy group, without
statistical differences for all the parameters investigated. A signiﬁcant reduction of the total number of
seizures (113.6 vs. 41.2; p = .01) was observed in patients in add-on therapy. The modiﬁcations of
epileptiform EEG abnormalities did not necessarily correlate with the self-reported clinical impressions.
Discussion: The quantiﬁcation of EDs monitored by A/EEG provides a useful objective support for
evaluating the neurophysiologic proﬁle and the real efﬁcacy of an antiepileptic treatment. In our patients
LEV was able to signiﬁcantly reduce the EDs only in add-on therapy. Further larger studies are necessary
to clarify the effects of LEV on electro-clinical features of generalized epilepsy.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Levetiracetam (LEV) is a new antiepileptic drug (AED) that has a
favorable safety proﬁle and no signiﬁcant interaction with other
AEDs or other drugs.1–4 The efﬁcacy and tolerability of LEV as
adjunctive therapy or monotherapy have been demonstrated in
patients with epileptic partial-onset seizures, with or without
secondary generalization.5–7 Recently, the efﬁcacy of LEV in
generalized idiopathic epilepsy has also been reported.8–13 Some
open-label studies indeed observed that LEV, in monotherapy or
add-on, reduces the frequency of myoclonic seizures in patients
with generalized epilepsy14 and may be effective and well
tolerated in resistant cases of juvenile myoclonic epilepsy.8,15
Moreover, Berkovic et al.16 demonstrated, in a randomized* Corresponding author at: Sapienza University of Rome, Department of
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doi:10.1016/j.seizure.2008.08.004placebo-controlled study, that LEV is effective as adjunctive
therapy also for treating generalized tonic–clonic seizures in
patients with idiopathic epilepsies.
Despite the several evidences of LEV efﬁcacy in the treatment of
generalized epilepsy, little information is reported in literature
regarding the effects of LEV on epileptiform discharges evaluated
objectively with EEG quantiﬁcation. Some experimental studies
showed that LEV attenuates spike andwave discharges in rats with
different genetic models of epilepsy with absences.17–19 Few case
reports and preliminary studies with long-term EEG recordings
conducted in patients affected by partial and generalized epilepsy
have also reported the efﬁcacy of LEV in the reduction of interictal
epileptiform discharges.20–23
Long-term EEG recording provides a reliable and objective
documentation of the efﬁcacy of an antiepileptic treatment,
through the quantitative evaluation of the epileptic activity.
However, there is often a discrepancy between the patient self-
reported impressions and the objective neurophysiological eva-
luation of the response to the treatment. In particular, in
generalized epilepsy with absence seizures, it may be possiblevier Ltd. All rights reserved.
Ad
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frequency of the ictal episodes. Ambulatory EEG (A/EEG) is a simple
available tool in routine clinical practice to perform long-term
monitoring in outpatients.
Aim of this study was to evaluate the objective effect of LEV on
epileptiform discharges in patients with generalized epilepsy,
monitored with ambulatory EEG (A/EEG). The quantiﬁcation of
epileptiform discharges before and after LEV administration has
been also correlatedwith the self-reported clinical informations on
seizures frequency during the treatment.
2. Methods
Patients with idiopathic and cryptogenic generalized epilepsy
were enrolled in the study, according to the following inclusion
criteria: (a) recurrence of generalized seizures (absence, myoclonic
and/or tonic–clonic seizures) in the previously 3 months; (b)
presence on basal standard EEG (S/EEG) of generalized epilepti-
form discharges, evaluated before the onset of LEV treatment; (c)
normal cerebral MR imaging; (d) no evidence of relevant medical
and neuropsychiatric diseases.
At baseline, S/EEG tracings were recorded for 30 min, at rest
and during photostimulation and hyperventilation, with a
digital apparatus (Micromed, Italy) and sampled at a rate of
256 s1. According to the International 10-20 System, the
following scalp electrodes were applied: Fp2, Fp1, F8, F7, F4,
F3, C4, C3, T4, T3, T6, T5, P4, P3, O2 and O1. During EEG
recordings, heart and breathing rates were continuously
monitored. The baseline S/EEG was used for the characterization
of epileptic generalized discharges (bursts of spikes, polyspikes,
spike-and-wave complexes).
After the baseline S/EEG, each patient was submitted to
ambulatory EEG (A/EEG) recording, performed by a Brain Spy
MS-40 Ambulatory Recorder (Micromed). The following conven-
tional chloride disc electrodes, according to the International 10-
20 System, were applied on the scalp with EC2 (Grass-Telefactor)
adesive paste: Fp2, Fp1, T4, T3, C4, C3, O2 and O1. A/EEG lasted for
24 h, starting between 9:00 and 10:00 a.m., thus including active
and quiet awake and nocturnal sleep at home.Table 1
Patients characteristics.
Pts Age (years) Gender Seizure type AEDs at ﬁrst A
Monotherapy
1 57 F Absence, myoclonic –
2 17 F Myoclonic, GTCS –
3 25 M Absence, GTCS –
4 16 F Absence, GTCS –
5 18 F Absence –
6 39 F Absence, GTCS –
7 21 M Absence –
8 22 M Absence –
9 29 M Myoclonic, GTCS –
10 24 F Absence, GTCS –
11 32 F Absence, GTCS –
d-on
12 65 F Myoclonic, GTCS VPA
13 24 F Absence, GTCS VPA
14 20 M Absence, GTCS ETS
15 60 M Absence, GTCS VPA + PB
16 27 F Absence, GTCS VPA + PB + LTG
17 23 F Myoclonic, GTCS VPA
18 30 F Absence, GTCS LTG + TPM
19 25 M Absence, GTCS VPA
20 35 F Myoclonic, GTCS VPA + LTG
21 45 M Absence, GTCS PB
GTCS (generalized tonic–clonic seizures); LEV (levetiracetam), VPA (valproic acid), ETSAfter the baseline S/EEG and A/EEG recordings, LEV was
administered at the dosage of 1000–1500 mg/day, starting with
500 mg/day and increasing of 500 mg/day every 5th day. At
inclusion, 11 patients started LEV as monotherapy, being totally
untreated or drug-free since the past 3 months, and 10 patients
started LEV as add-on therapy, being already under other AED
treatment and pharmacoresistant (Table 1). All patients and their
relativeswere instructed to keep adetailed diary of seizures andof
normal activity of the daily living. The second A/EEG was
performed after a 4–6 months follow-up, during treatment with
LEV. A/EEG recordings were evaluated ofﬂine by two experts
neurophysiologists blinded to the treatment. Well-structured,
organized and well identiﬁable epileptiform pattern lasting at
least 1 s were considered for the inspective quantiﬁcation of
epileptic activity. Single spikes or sharp waves or the bursts of
duration of less than 1 s have not been considered for the
quantiﬁcation.
The epileptic activity, evaluated for each A/EEG before and
during LEV treatment, was quantiﬁed according to the following
parameters: 1, total number of discharges in 24 h (TN); 2, total
duration in seconds of all registered discharges in 24 h (TD); 3,
maximal duration (MaxD) andmedian duration (MedD) in seconds
of discharges. At follow-up, patients were required to return their
clinical diary with the self-evaluation of the efﬁcacy of therapy on
seizures control and the occurrence of adverse effects. On the basis
of these self-reported clinical information, patients were classiﬁed
as: (a) patients seizure-free; (b) patients improved (reduction in
seizures 50%); (c) patients with seizure frequency substantially
unchanged; (d) patients with worsening of seizures.
The study was approved by the local Ethical Committee and all
subjects gave their written informed consent.
3. Statistical analysis
Data were collected on an Excel datasheet and SPSS13 for
Macintosh was used to perform statistical analysis. Student’s
paired t-test and Wilcoxon signed rank test were used to
determine mean differences among the groups. Statistical sig-
niﬁcance was considered for p < .05./EEG AEDs at second A/EEG Follow-up (months) LEV (mg/die)
LEV 4 1500
LEV 6 1000
LEV 6 1000
LEV 4 1000
LEV 5 1500
LEV 5 1500
LEV 5 1000
LEV 6 1000
LEV 5 1500
LEV 5 1500
LEV 6 1500
LEV + VPA 6 1500
LEV + VPA 4 1000
LEV + ETS 6 1000
LEV + VPA + PB 4 1500
LEV + VPA + PB + LTG 5 1500
LEV + VPA 4 1000
LEV + LTG + TPM 4 1000
LEV + VPA 5 1500
LEV + VPA + LTG 5 1500
LEV + PB 6 1500
(ethosuximide), PB (phenobarbital), LTG (lamotrigine), TPM (topiramate).
Table 2
Total number (TN), total duration (TD, s), maximal duration (MaxD, s) and median duration (MedD, s) of epileptic discharges at A/EEG before and after LEV therapy in all
patients, in patients in monotherapy and in patients in add-on therapy (mean  S.D.).
Total number Total duration Maximal duration Median duration
Basal Follow-up Basal Follow-up Basal Follow-up Basal Follow-up
All patients 170.8  159.5 130.6  161.1 472.3  439.4 409.5  490.7 8.5  8.3 11.3  11.2 2.5  1 2.5  1.5
Monotherapy 222.8  193.5 212  190.3 534.7  470.5 598.2  600.9 6.1  6.3 6.9  8 2.3  0.9 2.2  1.2
Add-on 113.6  89.5 41.2  21.7* 381.7  407 202  206.4 11.1  9.8 16.2  31.3 2.7  1.1 2.9  1.7
* p = .01 in respect to basal condition.
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Twenty-one patients (8 men and 13 women, mean age
31.1  14.3 years) were included in this prospective study. The
patients were affected by idiopathic (n. 16) and cryptogenic (n. 5)
generalized epilepsy.
Out of the 21 patients enrolled, 11 were treated with LEV in
monotherapy and 10 in add-on therapy. Mean follow-up period
was 5 months. The detailed patients characteristics are shown in
Table 1. All patients completed the treatment period and no
relevant adverse event has been reported.
4.1. Quantiﬁcation of epileptic discharges
Considering all patients together (those treated with LEV in
monotherapy and those in add-on), we did not observe signiﬁcant
differences for each of the objective EEG parameters investigated
at follow-up after LEV treatment.
Considering the two groups separately, no statistical difference
was observed within the group of patients treated in monotherapy
with LEV for the EEG parameters. Only in the group of patients
treated with LEV in add-on therapy, a signiﬁcant reduction of the
total number of epileptform discharges was observed at follow-up
(Table 2 and Fig. 1).
Considering the individual response of each patient separately
(Table 3), we observed a higher variability in the response to LEV
within the monotherapy treated group: one patient (pt 7) showed
the total disappearance of epileptiform discharges, two patients
(pt 1, 8) showed a clear reduction of the discharges, ﬁve patients
were substantially unchanged (pt 2, 3, 9–11), and three patients (ptFig. 1. Graphic representation of the total number of epileptic discharges modiﬁcation
while the add-on group (right) shows a more homogeneous response with a signiﬁcan4–6) showed an increase of epileptiformdischarges. In the group of
patients treated with LEV in add-on therapy, the effects of LEV
were more homogeneous and the total number of epileptiform
discharges was signiﬁcantly reduced, even though in none of them
a total disappearance of epileptic discharges was observed (Table 3
and Fig. 1).
4.2. Clinical effects
Considering the self-reported clinical effects of LEV in all
patients at follow-up (Table 3), 9/21 referred to be seizure-free, 2/
21 reported a relevant decrease of seizures, 8/21 reported that the
frequency of seizure was substantially unchanged and 2/21
reported a worsening of seizures.
In the monotherapy group, 2/11 patients referred the disap-
pearance of seizures, 2/11 the decrease of frequency of seizure, 5/
11 were unchanged and 2/11 referred a clinical worsening. In the
add-on group, 7/10 patients referred the total disappearance of
seizures, while 3/10 referred that the frequency of seizures was
substantially unchanged.
4.3. Correlation of clinical effects with EEG quantiﬁcation of
epileptiform discharges
Considering all patients that reported to be seizure free or
improved at follow-up after LEV (11/21), only in one patient LEV
actually induced the disappearance of epileptiform discharges (pt
7); in 8 patients (pt 1, 8, 12, 16–18, 20, 21) epileptiform discharges
were reduced in number and in total duration. Of the remaining 2
patients self-reporting as being seizure free at follow-up, patient 5after LEV therapy. The monotherapy group (left) shows a heterogeneous response,
t reduction of the number of epileptic discharges.
Table 3
Total number (TN), total duration (TD, s), maximal duration (MaxD, s) and median duration (MedD, s) of spike-wave discharges at A/EEG at basal and follow-up after LEV
therapy in the single subjects.
Pt TN TD MaxD MedD Self-reported seizures
Basal Follow-up Basal Follow-up Basal Follow-up Basal Follow-up
Monotherapy
1 567 110 977 123 3 2 2 1 Decrease
2 184 191 401 585 5 8 2 3 Increase
3 614 654 1115 1420 7 12 2 2 Unchanged
4 20 30 34 50 3 4 2 1.5 Unchanged
5 221 335 1583 1914 25 29 5 4 Seizure-free
6 133 394 321 944 4 4 2 2 Unchanged
7 94 0 212 0 4 0 2 0 Seizure-free
8 120 108 310 285 4 2 2 1 Decrease
9 260 255 513 487 4 4 2 3 Unchanged
10 153 165 428 400 6 5 3 3 Unchanged
11 85 90 208 373 3 6 2 4 Increase
Add-on
12 111 44 166 53 2 2 1 1 Seizure-free
13 28 14 105 37 7 7 3 2 Unchanged
14 101 53 179 219 5 11 1 4 Seizure-free
15 63 40 456 688 30 105 4 7 Unchanged
16 304 47 1405 138 27 10 4 2 Seizure-free
17 137 67 283 132 4 4 2 2 Seizure-free
18 27 10 67 28 8 5 2 2 Seizure-free
19 87 50 185 178 8 7 3 3 Unchanged
20 50 15 257 119 5 3 3 2 Seizure-free
21 228 72 715 428 15 8 4 4 Seizure-free
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duration of discharges, butwith a reduction of themedian duration
(4 s vs. 5 s) (Fig. 2); on the contrary, patient 14 showed a reduced
number of the total discharges, but with a higher median duration
(4 s vs. 1 s).
In the patients reporting no beneﬁt after LEV (8/21), three
patients (pt 13, 15, 19) showed a reduction of the number of
discharges, two patients (pt 4, 6) showed an increase and three
patients (pt 3, 9, 10) were substantially unchanged.
In the 2 patients self-reporting an increase of seizures (pt 2, 11),
the total number of discharges was substantially unvaried, but
with an effective increase of their maximal (pt 2: 8 s vs. 5 s, pt 11:
6 s vs. 3 s) and median (pt 2: 3 s vs. 2 s, pt 11: 4 s vs. 2 s) duration.
5. Discussion
LEV has an antiepileptic effect in a broad range of animal
models thatmimic generalized epilepsy inman, including different
genetic models of absence epilepsy in rats.17–19 In particular, the
clinical beneﬁt of LEV therapy observed in young rats with absence
seizures seems to be correlated with a reduction of spike-and-
wave discharges evaluated at EEG monitoring.18
Few human studies have been performed to investigate the
effects of LEV on epileptiform EEG discharges and data are not
comparable, due to the different methodological approaches
applied. Nonetheless, even if evaluated through different para-
meters, an overall positive effect of LEV on interictal epileptiform
activity has been reported in patients with idiopathic generalized
epilepsy. Rocamora et al.23 evaluated 8 patients treatedwith LEV (4
in mono- and 4 in add-on therapy) for refractory primary
generalized epilepsy with long-term EEG recording. The para-
meters evaluated were the spike-wave median density (spike/h),
themedian spike-wave burst duration (s) and themaximum spike-
wave burst duration (s), and they observed that LEV induces a
consistent long-term reduction of interictal epileptiform activity,
also correlated with a clinically relevant antiepileptic effect. All of
the patients received previous AED drugs and, in 3 of the 4 patients
in add-on therapy, the previous treatmentwasmodiﬁed. Gallagheret al.22 reported similar results evaluating spike-wave density and
duration of interictal spike-wave complexes in 10 patients treated
with LEV for idiopathic generalized epilepsy and monitored by
continuous video/EEG monitoring. Only one study used A/EEG24
but, even though an improvement after LEV treatment with a 60%
reduction of EEG discharges or a total disappearance of ictal/
interictal EEG abnormalities is reported, neither objective data nor
the A/EEG quantiﬁcation methods are provided.
In our experience, epileptiform pattern quantiﬁcation with A/
EEG before and after the initiation of an antiepileptic treatment is a
very useful tool to evaluate the real antiepileptic effect of an AED.
To obtain an objective, reliable and comparable measurement of
the epileptic activity in the 24 h A/EEG recording, we evaluated the
total number of discharges, their total duration in the 24 h, and the
maximal and median discharge duration.
In the present study we have selected a small group of patients
with idiopathic or cryptogenic generalized epilepsy, with well-
structured and clearly identiﬁable generalized epileptic pattern at
standard EEG, and treatedwith LEV both inmonotherapy aswell as
in add-on therapy. Our main result is the consistent reduction of
generalized epileptic activity only in the group of patients treated
with LEV in add-on. The signiﬁcant reduction of the total number of
discharges was also correlated with the self-reported decreased
incidence of clinical seizures in this group of patients.
Nonetheless, the effects of LEV monotherapy on epileptic
discharges are heterogeneous, and also correspond to a high
variability in the self-reported clinical efﬁcacy. As a matter of fact,
among the two patients referring to be seizure-free at follow-up,
only one actually showed the disappearance of the epileptiform
activity at A/EEG, while in the other patient epileptiform
discharges were shorter, but paradoxically increased in number.
Even if the latter reported a beneﬁcial effect from AED therapy, it
cannot be concluded in this case that the drug had itself a positive
effect, since the patient probably did not perceive the seizures,
because they were shorter. On the contrary, in the 2 patients
reporting a clinical worsening, the number of discharges was
unvaried, but with an increase of maximal and median duration of
discharges. The lack of drug efﬁcacy and statistical power in the
Fig. 2. Epileptic discharges at basal A/EEG (A) and at follow-up A/EEG (B) in patient no. 5, reporting the disappearance of absences after LEV therapy. Note the reduced duration
of epileptic discharges duration at A/EEG, but the increased number of seizures at the 24 h1 quantiﬁcation (C).
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the response and to the small number of patients included.
These data should however be considered cautiously, for
the limitations of this study related to the small number of
patients with a heterogeneous number of discharges before
treatment, to the different disease history and to the short
follow-up period.
Considering the clinical–electrophysiological correlation, it is
though evident that, in our patients, self-reported clinical beneﬁt
does not necessarily correspond to a reduction of epileptiform
activity. This reﬂects the fact that the distinction between interictal
and ictal discharges is a confusing matter in generalized epilepsy:
it is clear that the duration of a single discharge is a crucial point in
determining the subjective perception of an absence, and that
epileptic discharges shorter than 3 s are not able to determine
periods of altered responsiveness. For these reasons, quantitative
neurophysiological evaluation of both ictal and interictal epilepti-
form activitymay be useful, togetherwith the clinical self-reported
impressions, to objectively assess the global effects of an
antiepileptic drug.
Another point that has to be underlined is that the partial
EEG response to LEV treatment in our patients might be related
to the low dosages administered (1000–1500 mg/day). This was
due to ethic reasons in the monotherapy treated group, in which
LEV is not authorized alone for the treatment of generalized
epilepsy, and to avoid sedative adverse effects in the add-on
group. In these regards we could report that some patients (pt 3,
14, 15), treated with higher LEV dosages (2500 mg/die) after the
end of the study, did not show an effective reduction of
epileptiform discharges.6. Conclusions
Our data show that the objective quantiﬁcation of epileptiform
dischargeswith A/EEG is a useful tool for the complete evaluation of
the efﬁcacy of an antiepileptic treatment. A/EEG is amodern system
of continuous EEG monitoring, easily applicable in routine clinical
practicewith low costs and high sensitivity. Thedetailed quantiﬁca-
tion of the epileptic activitywith A/EEG, easy to be performed, helps
the deﬁnition of a neurophysiologic proﬁle of an antiepileptic
treatment that may be used for further follow-up analyses. The
correlation of discharges quantiﬁcation with the clinical self-
reported impressions may also clearly identify those patients with
an ‘‘electro-clinical dissociation’’, in which the drug induces a
relevant clinical improvement, but only a decrease of the discharges
duration without a signiﬁcant modiﬁcation of the total epileptic
activity. We suggest that this method, with proper objective
quantiﬁcation, could be of help in monitoring clinical and electro-
physiological responses to AEDs. Further studies on a larger number
of patients will clarify the effects of LEV on epileptiform generalized
discharges. InourpatientswithgeneralizedepilepsyLEVseemstobe
more effective in add-on therapy than in monotherapy.
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